News Releases

Month Year

Email Alerts

May 22, 2023

Insmed Presents Range of New Study Findings at American Thoracic Society 2023 International Conference
May 8, 2023

Insmed Unveils New Research Platforms and Capabilities at Investor and Analyst Event, "The Future of Rare at Insmed: Functional Genes, AI-Enhanced Proteins, Glowing Algae, and More"
May 5, 2023

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
May 4, 2023

Insmed Reports First Quarter 2023 Financial Results and Provides Business Update
Apr 24, 2023

Insmed to Host Investor and Analyst Event on May 8, 2023
Apr 20, 2023

Insmed to Host First Quarter 2023 Financial Results Conference Call on Thursday, May 4, 2023
Apr 6, 2023

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Mar 31, 2023

Insmed Completes Enrollment of Adult Patients in Phase 3 ASPEN Study of Brensocatib in Bronchiectasis
Mar 24, 2023

Insmed to Present New Clinical, Pre-Clinical, and Real-World Data in Serious and Rare Lung Diseases at the American Thoracic Society 2023 International Conference
Mar 3, 2023

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Mar 1, 2023

Insmed To Present at Two March Conferences
Feb 23, 2023

Insmed Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
Feb 9, 2023

Insmed to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call on Thursday, February 23, 2023
Feb 7, 2023

Insmed To Present at the SVB Securities Global Biopharma Conference
Feb 3, 2023

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Jan 20, 2023

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Jan 6, 2023

Insmed Provides Business Updates and Near-Term Strategic Outlook at 41st Annual J.P. Morgan Healthcare Conference
Jan 3, 2023

Insmed To Present at the 41st Annual J.P. Morgan Healthcare Conference
Dec 6, 2022

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Nov 30, 2022

Insmed To Present at the Nasdaq 47th Investor Conference
Nov 4, 2022

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Nov 1, 2022

Insmed To Present at Three November Conferences
Oct 27, 2022

Insmed Ranks No. 1 on Science's 2022 Top Biopharma Employers List
Oct 27, 2022

Insmed Reports Third Quarter 2022 Financial Results and Provides Business Update
Oct 19, 2022

Insmed Announces Strategic Financings Totaling $775 Million

Show per page

Stay In The Loop

Want to stay up to date on our news, events, and filings? Set up your
email alerts.

View the latest Insmed Investor Presentation

Download

Su	Mo	Tu	We	Th	Fr	Sa

Su	Mo	Tu	We	Th	Fr	Sa

Our Global Company

Current Clinical Trials

Our Research Team

Our Global Company

Current Clinical Trials

Our Research Team

Footer